Full notification file
Member State to which the notification was sent
Date of acknowledgement from the Member State Competent Authority
Title of the Project
Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv candidate HIV-1 vaccines in recently HIV-1 infected individuals with early viral suppression after initiation of antiretroviral therapy (HAART)
Proposed period of release:
01/01/2012 to 31/12/2012
Name of the Institute(s) or Company(ies)
IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol
Carretera de Canyet s/n
08916 Badalona (Barcelona);
3. Is the same GMO release planned elsewhere in the Community?
Has the same GMO been notified elsewhere by the same notifier?
If yes, notification number(s):
GMO is a:
Identity of the GMO:
The final GMO ChAdV63.HIVconsv is a life recombinant replication-incompetent
chimpanzee adenovirus (ChAdV63) that harbors the codifying sequence for the HIV-1
specific T-cell immunogen HIVconsv.
Information relating to the recipient or parental organisms from wich the GMO is derived
Chimpanzee adenovirus 63
Serotype 63 from chimpanzee adenovirus
European Commission administrative information
Consent given by the Member State Competent Authority: